EUVIMEDEUVIMED entdecken
Open Access

Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy

Xiao-Ting Xie iD, Meng Guan iD, Kai Cheng iD, Yong Li, Bin Zhang, Yi-Tong Zhou, Lin-Fang Tan, Peng-Shuo Dong, Si Chen iD, Bo Liu iD, Yuan-Di Zhao iD, Jin-Xuan Fan iD

Science Advances · 28.03.2025 · 11 (13)

DOI: 10.1126/sciadv.adt7298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 28.03.2025. Verfasst von Xiao-Ting Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laborato…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Escherichia coli. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor immune checkpoint therapy (ICT) aims to block immune escape signals between tumor and immune cells. However, low delivery efficiency of immune checkpoint inhibitors (ICIs), narrow single-target approach, and reduced responsiveness notably hinder clinical development of ICT. Here, we developed a nanoliposome-bacteria hybrid system that acts as an antibody (Ab) factory, enabling precise tumor targeting and macrophage activation in hypoxic environments. We reprogrammed attenuated Escherichia coli MG1655 to synthesize CD47 antibodies (aCD47) in response to hypoxic tumor microenvironments while surface conjugating with redox-responsive macrophage colony-stimulating factor-loaded liposomes. This system leverages bacterial tropism to enhance macrophage infiltration and polarization. The low oxygen levels trigger in situ aCD47 expression, blocking the “do not eat me” signal and boosting macrophage antitumor activity. In addition, macrophage antigen presentation activates CD8+CD3+ T cells, amplifying systemic antitumor immunity. Analysis of the gut microbiome shows reduced pathogenicity and improved intestinal tolerance with increased probiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsEscherichia coliAnimalsMiceTumor MicroenvironmentHumansMacrophagesLiposomesCD47 AntigenCell Line, TumorImmunotherapyGastrointestinal MicrobiomeMacrophage Activation

Substanzen

Immune Checkpoint InhibitorsLiposomesCD47 Antigen

Autor:innen und Institutionen

  • Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Department of Biomedical Engineering, College of Life Science and…
  • Hubei Key Laboratory of Plasma Chemistry and Advanced Materials, School of Material Science and Engineering, Wuhan Institute of Technology, Wuhan 430205, Hubei, P. R. China.
  • NMPA Research Base of Regulatory Science for Medical Devices & Institute of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan 430074, Hubei, P. R. China.

ORCID-Profile: Xiao-Ting Xie, Meng Guan, Kai Cheng, Si Chen, Bo Liu, Yuan-Di Zhao, Jin-Xuan Fan

Zitieren

APA

Xie, X. T., Guan, M., Cheng, K., Li, Y., Zhang, B., Zhou, Y. T., Tan, L. F., Dong, P. S., Chen, S., Liu, B., Zhao, Y. D., & Fan, J. X. (2025). Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy. Science Advances, 11(13). https://doi.org/10.1126/sciadv.adt7298

Vancouver

Xie XT, Guan M, Cheng K, Li Y, Zhang B, Zhou YT, et al. Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy. Science Advances. 2025;11(13). doi:10.1126/sciadv.adt7298

BibTeX
@article{Xie2025,
  author = {Xie, Xiao-Ting and Guan, Meng and Cheng, Kai and Li, Yong and Zhang, Bin and Zhou, Yi-Tong and Tan, Lin-Fang and Dong, Peng-Shuo and Chen, Si and Liu, Bo and Zhao, Yuan-Di and Fan, Jin-Xuan},
  title = {Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {13},
  doi = {10.1126/sciadv.adt7298}
}
Kostenlos starten →